Purpose: This study was conducted to evaluate bone resorption around implants placed in alveolar bone previously subjected to distraction osteogenesis (DO).
Patients And Methods: The study included 9 patients who had undergone alveolar DO with subsequent placement of 37 implants. None of the implants was lost. Vertical peri-implant bone deficit was measured on the distal and mesial surfaces from panoramic radiographs obtained at implant loading and again 1 year later. Resorption over the year of loading was calculated as the increase in vertical bone deficit.
Results: Mean peri-implant bone resorption over the first year after loading was 0.60 mm mesially and 0.68 mm distally. In both cases, the resorption (ie, the difference between the mean bone deficit at loading and 1 year later) was statistically significant (P < .05).
Conclusion: Vertical bone resorption around implants placed in distracted alveolar bone is similar to that seen around implants placed in nondistracted bone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.joms.2007.12.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomimetic Extracellular Vesicles Containing Biominerals for Targeted Osteoporosis Therapy.
ACS Appl Mater Interfaces
January 2025
Organoid Research Center, Institute of Translational Medicine, Shanghai University, Shanghai 200444, People's Republic of China.
Osteoporosis (OP) is a systemic skeletal disorder characterized by decreased bone mineral density and a heightened risk of fractures. Therapies for OP have primarily focused on balancing bone formation and bone resorption, but enhancing the remineralization of osteoporotic bone is also a key strategy for effective repair. Recent insights into biomineralization mechanisms have highlighted the essential role of mineral-containing extracellular vesicles (EVs) secreted by osteoblasts in promoting bone marrow mesenchymal stromal/stem cell (BMSC) differentiation and initiating matrix mineralization.
View Article and Find Full Text PDF3-MA attenuates collagen-induced arthritis in vivo via anti-inflammatory effect and autophagy inhibition.
BMC Musculoskelet Disord
January 2025
Tianjin Institute of Environmental and Operational Medicine, Tianjin, 300050, China.
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease which afflicts about nearly 1% of global population. RA results in synovitis and cartilage/bone damage, even disability which aggravates the health burden. Many drugs are used to relieve RA, such as glucocorticoids (GCs), non-steroidal anti-inflammatory drugs (NSAIDs), and disease-modifying anti-rheumatic drugs (DMARDs) in the clinical treatment.
View Article and Find Full Text PDF[Influencing fracture healing by specific osteoporosis medications].
Z Rheumatol
January 2025
Institut für Muskuloskelettale Medizin, LMU Klinikum, LMU München, München, Deutschland.
Background: Osteoporosis is a widespread disease defined by a reduction in bone mass and structure, thereby increasing the risk of fragility fractures. Treatment typically involves specific medications, which either inhibit bone resorption (antiresorptive) or stimulate bone formation (anabolic) and may potentially influence the healing of osteoporotic fractures. On the other hand, metabolic disorders, immune system dysfunctions or circulatory problems can impair fracture healing.
View Article and Find Full Text PDFAlthough the toxic effect of Sedentary behavior (SED) on bone health has been demonstrated in the previous study, the underlying mechanisms of SED, or break SED to bone health remain unclear. In this study, we aim to investigate the effects of sedentary behavior (SED) on bone health, as well as the potential favor effects of moderate to vigorous physical activity (MVPA) and periodic interruptions of SED. To simulate SED, we used small Plexiglas cages (20.
View Article and Find Full Text PDFSynthesis and Structure-Activity Relationships of Novel Benzofuran Derivatives with Osteoblast Differentiation-Promoting Activity.
Chem Pharm Bull (Tokyo)
January 2025
Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd.
Osteoporosis is caused by an imbalance between bone resorption and formation, which decreases bone mass and strength and increases the risk of fracture. Therefore, osteoporosis is treated with oral resorption inhibitors, such as bisphosphonates, and parenteral osteogenic drugs, including parathyroid hormone and antisclerostin antibodies. However, orally active osteogenic drugs have not yet been developed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!